Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
4.3
63.08%
60%
—
-63.88%
20%
—
5 Years
Score4.3
Net Growth63.08%
Net Trend60%
Net Income Consistency—
Rev Growth-63.88%
Rev Trend20%
Revenue Consistency—
Nektar Therapeutics fundamental performance
Between 2020 and 2025, revenue declined from $ 152M to $ 55M and net income went from -$ 444M to -$ 164M. Revenue increased in 1 of those 5 years; net income in 3.
Across Nektar Therapeutics's full reported history, from 1994 to 2025, revenue grew from $ 1M to $ 55M and net income went from -$ 5M to -$ 164M. Revenue increased in 71% of the years measured; net income in 42%.
Nektar Therapeutics currently holds a 20-year HDB Score of 2.6 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 76.03 | — |
1 Year2025-08-12 | $ 23.60 | 222.16% |
5 Years2021-08-12 | $ 214.50 | -64.55% |
10 Years2016-08-12 | $ 257.40 | -70.46% |
20 Years2006-08-11 | $ 242.55 | -68.65% |
30 Years1996-08-12 | $ 111.56 | -31.85% |
All Time1994-05-03 | $ 56.25 | 35.16% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | 30 Years1996-08-12 | All Time1994-05-03 |
|---|---|---|---|---|---|---|---|
| Price | $ 76.03 | $ 23.60 | $ 214.50 | $ 257.40 | $ 242.55 | $ 111.56 | $ 56.25 |
| Return | — | 222.16% | -64.55% | -70.46% | -68.65% | -31.85% | 35.16% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2025 | $ 55M | -$ 164M | $ 245M |
| 2024 | $ 98M | -$ 118M | $ 255M |
| 2023 | $ 90M | -$ 276M | $ 303M |
| 2022 | $ 92M | -$ 368M | $ 504M |
| 2021 | $ 101M | -$ 523M | $ 733M |
| 2020 | $ 152M | -$ 444M | $ 1.06B |
| 2019 | $ 114M | -$ 440M | $ 1.32B |
| 2018 | $ 1.19B | $ 681M | $ 1.33B |
| 2017 | $ 307M | -$ 96M | $ 296M |
| 2016 | $ 165M | -$ 153M | $ 389M |
| 2015 | $ 230M | -$ 81M | $ 308M |
| 2014 | $ 200M | -$ 53M | $ 237M |
| 2013 | $ 148M | -$ 162M | $ 237M |
| 2012 | $ 81M | -$ 171M | $ 277M |
| 2011 | $ 71M | -$ 133M | $ 241M |
| 2010 | $ 159M | -$ 37M | $ 315M |
| 2009 | $ 71M | -$ 102M | $ 396M |
| 2008 | $ 90M | -$ 34M | $ 378M |
| 2007 | $ 273M | -$ 32M | $ 482M |
| 2006 | $ 217M | -$ 154M | $ 458M |
| 2005 | $ 126M | -$ 185M | $ 476M |
| 2004 | $ 114M | -$ 101M | $ 418M |
| 2003 | $ 106M | -$ 46M | $ 285M |
| 2002 | $ 94M | -$ 107M | $ 293M |
| 2001 | $ 77M | -$ 250M | $ 344M |
| 2000 | $ 51M | -$ 97M | $ 484M |
| 1999 | $ 41M | -$ 38M | $ 138M |
| 1998 | $ 21M | -$ 18M | $ 82M |
| 1997 | $ 16M | -$ 9M | $ 100M |
| 1996 | $ 6M | -$ 10M | $ 18M |
| 1995 | $ 3M | -$ 7M | $ 3M |
| IPO1994 | $ 1M | -$ 5M | $ 10M |
Explore beyond NKTR
You're looking at Nektar Therapeutics. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
